PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Osteoporosis.

Abstract Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy should be started and choice of medication and duration of treatment will maximize the benefits of fracture prevention while minimizing potential harms of long-term drug exposure.
PMID
Related Publications

Clinician's Guide to Prevention and Treatment of Osteoporosis.

Preventing osteoporosis-related fractures: an overview.

Screening for osteoporosis: recommendation statement.

Screening for osteoporosis.

Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.

Authors

Mayor MeshTerms
Keywords
Journal Title annals of internal medicine
Publication Year Start




PMID- 28761958
OWN - NLM
STAT- MEDLINE
DA  - 20170801
DCOM- 20170808
LR  - 20170808
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 167
IP  - 3
DP  - 2017 Aug 01
TI  - Osteoporosis.
PG  - ITC17-ITC32
LID - 10.7326/AITC201708010 [doi]
AB  - Osteoporosis is a common systemic skeletal disorder resulting in bone fragility
      and increased fracture risk. However, management of osteoporosis and fracture
      prevention strategies are often not addressed by primary care clinicians, even in
      older patients with recent fractures. Evidence-based screening strategies will
      improve identification of patients who are most likely to benefit from drug
      treatment to prevent fracture. In addition, careful consideration of when
      pharmacotherapy should be started and choice of medication and duration of
      treatment will maximize the benefits of fracture prevention while minimizing
      potential harms of long-term drug exposure.
FAU - Ensrud, Kristine E
AU  - Ensrud KE
AD  - From the University of Minnesota and Veterans Affairs Health Care System,
      Minneapolis, Minnesota; and the University of California, Los Angeles,
      California.
FAU - Crandall, Carolyn J
AU  - Crandall CJ
AD  - From the University of Minnesota and Veterans Affairs Health Care System,
      Minneapolis, Minnesota; and the University of California, Los Angeles,
      California.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Calcium, Dietary)
RN  - 1406-16-2 (Vitamin D)
SB  - AIM
SB  - IM
MH  - Absorptiometry, Photon
MH  - Bone Density
MH  - Bone Density Conservation Agents/therapeutic use
MH  - Calcium, Dietary/administration & dosage
MH  - Female
MH  - Humans
MH  - Male
MH  - Mass Screening
MH  - Osteoporosis/complications/*diagnosis/*drug therapy
MH  - Osteoporosis, Postmenopausal/complications/diagnosis
MH  - Osteoporotic Fractures/*prevention & control
MH  - Risk Assessment
MH  - Risk Factors
MH  - Vitamin D/administration & dosage
EDAT- 2017/08/02 06:00
MHDA- 2017/08/09 06:00
CRDT- 2017/08/02 06:00
AID - 2646658 [pii]
AID - 10.7326/AITC201708010 [doi]
PST - ppublish
SO  - Ann Intern Med. 2017 Aug 1;167(3):ITC17-ITC32. doi: 10.7326/AITC201708010.